NEURAL-CONCEPT
4.6.2024 11:01:28 CEST | Business Wire | Press release
Neural Concept, the leading Engineering Intelligence platform that transforms product design with 3D Deep Learning, has announced that it has raised $27 million in a Series B funding round. The round was led by Forestay Capital, with the D. E. Shaw group and existing investors Alven, CNB Capital, HTGF, and Aster Group also participating. This round follows the company’s $9 million Series A round in March 2022 and $2 million Seed round in 2020. Funds raised in this latest round will be used to consolidate Neural Concept’s technology leadership in the field, as well as to accelerate its global recruitment and growth to meet strong customer demand across Europe, Asia-Pacific, and the US.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240531755430/en/
Neural Concept, the leading Engineering Intelligence platform that transforms product design with 3D Deep Learning, has raised $27 million in a Series B funding round. The round was led by Forestay Capital, with the D. E. Shaw group and existing investors Alven, CNB Capital, HTGF, and Aster Group also participating. (Graphic: Business Wire)
Manufacturers globally are facing unprecedented challenges. The need for improved performance, safety, and sustainability is increasing, while pressure to reduce costs and accelerate innovation continues to rise. Neural Concept solves these challenges by empowering engineering teams to develop better products faster using AI.
Founded in 2018 and headquartered in Lausanne, Switzerland, Neural Concept has more than 60 employees across Switzerland, Germany, and the US, and is the leader in 3D Deep Learning for product engineering teams in the Automotive, Micro-electronics, Aerospace, and Energy industries. More than 60 Original Equipment Manufacturers including Airbus, Bosch, General Electric, Subaru – and four out of ten Formula 1 racing teams – rely on Neural Concept’s platform to place Engineering Intelligence at the heart of their product development process.
The platform combines Neural Concept’s proprietary technology with unique data analysis, MLOps, and application deployment capabilities to make Engineering Intelligence central to the product simulation and development processes. It dramatically improves collaboration across data-science, simulation, and design teams in order to enhance and accelerate innovation. Neural Concept is proven to reduce end-to-end product development times by up to 75%; accelerate product simulation by up to 10x; and improve product characteristics, including efficiency, safety, speed, and aerodynamics, by up to 30%.
The Series B funding news follows the recent unveiling of a close technical collaboration with NVIDIA, allowing Neural Concept to optimize performance of physics-driven deep learning models on NVIDIA GPUs and CUDA software and to jointly push the frontiers of the field.
Deborah Pittet, Senior Principal at lead investor Forestay Capital said, “Neural Concept has pioneered 3D Deep Learning – the leading-edge of AI – and demonstrated phenomenal traction and results with customers in various industries around the world. We are thrilled to be partnering with the company’s world-class visionary team and lead this significant Series B, which will accelerate its global growth and reshape the way engineering companies around the world develop and design products.”
Jean Nations at the D. E. Shaw group said, “We are excited to embark on this journey with Neural Concept and to support its growth. We believe Neural Concept can be a powerful accelerant for product engineering teams bringing products to market, as demonstrated by the dozens of global manufacturers already utilizing its innovative platform. This funding helps position Neural Concept to extend Engineering Intelligence to many more.”
Pierre Baqué, Co-founder and CEO at Neural Concept said, “The world is facing unprecedented global challenges that urgently require innovative engineering solutions. Engineering teams are under enormous pressure to deliver smarter, safer, and more sustainable products faster – but to do this requires a fundamentally new approach. Neural Concept allows Original Equipment Manufacturers to place leading-edge 3D Deep Learning and Generative AI right at the heart of their product development – improving collaboration and processes while helping identify innovative solutions. We are delighted to work with our new investors Forestay Capital and the D. E. Shaw group and all of our existing investors to take the company to the next level. This $27 million Series B funding round will allow us to build on our strong commercial success and help more OEMs around the world harness the full potential of Engineering Intelligence to deliver better products faster.”
Watch the video to learn more about Neural Concept and Engineering Intelligence:
Editors Notes
About Neural Concept: www.neuralconcept.com
Founded in 2018, Neural Concept provides a leading end-to-end platform which places 3D AI at the center of the product development process to revolutionize the way engineers conceptualize, design, and validate products with Engineering Intelligence. The company – which was spun out from the Swiss Federal Institute of Technology in Lausanne (EPFL) and is backed by world renowned investors including Forestay Capital, the D. E. Shaw group, Alven, CNB Capital, HTGF, and Aster Group – works with 40% of the largest European and Asian OEMs and 25% of the world’s top 100 tier-1 suppliers.
About Forestay Capital: www.forestay.vc
Founded in 2018, Forestay is an early-growth stage tech fund and part of B-FLEXION, an entrepreneurial private investment firm founded by Ernesto Bertarelli. Forestay invests in visionary teams reaching growth inflection points and partners with them to create future category leaders. The fund supports start-ups with investments between $10M and $20M in Europe, Israel, and opportunistically on the East Coast of the US.
About The D. E. Shaw Group: www.deshaw.com
The D. E. Shaw group is a global investment and technology development firm with more than $60 billion in investment capital as of March 1, 2024, and offices in North America, Europe, and Asia. Since the D. E. Shaw group’s founding in 1988, the firm has earned a reputation for successful investing based on innovation, careful risk management, and the quality and depth of its staff. The D. E. Shaw group has a significant presence in the world's capital markets, investing in a wide range of companies and financial instruments in both developed and developing economies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240531755430/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom